Key Points

  • Lululemon’s second-quarter revenue fell 4% to $2.42 billion, missing Wall Street expectations of about $2.46 billion.
  • The company cut its full-year revenue forecast to $10.35 billion-$10.5 billion, implying a 5%-7% decline, while adjusted earnings guidance fell to $9.48-$9.73 per share.
  • Shares fell roughly 18% in extended trading as investors focused on weakening demand, tougher competition and the challenge facing incoming CEO Heidi O’Neill.
hero

Lululemon is facing a deeper slowdown in its core business as weaker demand and intensifying competition pressure sales in North America. The athletic-apparel company’s latest forecast reduction adds to concerns about its ability to restore brand momentum at a time when consumers remain selective and newer rivals such as Alo Yoga and Vuori continue gaining attention.

Revenue Declines as Core Sales Weaken

Lululemon reported second-quarter revenue of $2.42 billion for the period ended August 2, down 4% from a year earlier and below analysts’ expectations of approximately $2.46 billion. Comparable sales declined 9%, highlighting weakness beyond the headline revenue figure. Sales in the Americas fell 8%, while international revenue increased 4%, showing that the slowdown is particularly concentrated in the company’s most important market.

Net income declined to $329.2 million, or $2.92 per diluted share, from $370.9 million, or $3.10 per share, a year earlier. The earnings figure benefited from a $134.5 million tariff refund and related interest, equivalent to about 86 cents per share, making the underlying sales weakness more important for investors assessing the quarter.

Full-Year Outlook Takes Another Hit

Lululemon now expects fiscal 2026 revenue of $10.35 billion to $10.5 billion, representing a 5% to 7% decline. That compares with its previous forecast of revenue remaining flat or declining by as much as 1%, marking another substantial reduction in expectations.

The company also lowered its full-year adjusted earnings-per-share outlook to $9.48-$9.73, compared with its previous forecast of $10.95-$11.15. For the third quarter, Lululemon expects revenue of approximately $2.29 billion to $2.32 billion, indicating that management does not expect a rapid recovery in the near term.

The weaker outlook reflects concerns about product momentum and consumer response. Sales of the company’s signature leggings have reportedly declined by about 20%, while the broader shift toward looser-fitting athletic apparel illustrates the changing preferences Lululemon must address.

New Leadership Faces a Difficult Reset

The results arrive just days before Heidi O’Neill, a former Nike executive, takes over as Lululemon’s new CEO. Her immediate challenge will be to rebuild momentum in the Americas while strengthening product innovation and marketing without undermining the premium positioning that has historically supported the brand’s growth.

Lululemon has already reduced its store-opening plans for the year to 35 locations from an earlier target of 40, signaling a more cautious approach to expansion. At the same time, competition from newer athletic and lifestyle brands is increasing pressure on the company to refresh its product assortment and reconnect with consumers.

The sharp share-price reaction shows how much investor expectations have shifted around Lululemon. The stock fell about 18% in extended trading following the results, adding to a prolonged decline. Going forward, investors will be watching whether O’Neill can stabilize North American sales, improve product demand and restore growth while controlling costs. The pace of recovery in comparable sales, international expansion and the company’s ability to regain relevance among younger consumers will be central to determining whether the current downturn is cyclical or reflects a deeper change in Lululemon’s competitive position.


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Could Tesla’s China Sales Rebound Sustain Its Stock Rally Despite Margin Pressures?
    • Lior mor
    • •
    • 7 Min Read
    • •
    • ago 22 hours

    SKN | Could Tesla’s China Sales Rebound Sustain Its Stock Rally Despite Margin Pressures? SKN | Could Tesla’s China Sales Rebound Sustain Its Stock Rally Despite Margin Pressures?

    Tesla shares advanced on October 9 after new figures showed continued growth in sales of vehicles produced at the company’s

    • ago 22 hours
    • •
    • 7 Min Read

    Tesla shares advanced on October 9 after new figures showed continued growth in sales of vehicles produced at the company’s

    SKN | Indian Stocks Set to Rebound After Selloff as Rising Oil Prices Threaten Gains
    • Lior mor
    • •
    • 6 Min Read
    • •
    • ago 2 days

    SKN | Indian Stocks Set to Rebound After Selloff as Rising Oil Prices Threaten Gains SKN | Indian Stocks Set to Rebound After Selloff as Rising Oil Prices Threaten Gains

    Indian shares were poised to recover at the open on Friday after a sharp selloff pushed benchmark indexes to multi-year

    • ago 2 days
    • •
    • 6 Min Read

    Indian shares were poised to recover at the open on Friday after a sharp selloff pushed benchmark indexes to multi-year

    SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments.
    • omer bar
    • •
    • 6 Min Read
    • •
    • ago 2 days

    SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments. SKN | Viatris will acquire Pacira BioSciences for $1.65 billion, expanding its presence in non-opioid pain treatments.

    Viatris has agreed to acquire Pacira BioSciences for $1.65 billion, expanding its portfolio of branded medicines as pharmaceutical companies seek

    • ago 2 days
    • •
    • 6 Min Read

    Viatris has agreed to acquire Pacira BioSciences for $1.65 billion, expanding its portfolio of branded medicines as pharmaceutical companies seek

    SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion
    • Ronny Mor
    • •
    • 6 Min Read
    • •
    • ago 2 days

    SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion SKN | RTX’s Raytheon Wins Missile Defense Contract Worth Up to $6.3 Billion

    RTX’s Raytheon has secured a U.S. military contract valued at up to $6.3 billion, adding another major award to a

    • ago 2 days
    • •
    • 6 Min Read

    RTX’s Raytheon has secured a U.S. military contract valued at up to $6.3 billion, adding another major award to a